Request Demo
Last update 24 May 2025
Methylprednisolone sodium succinate
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Methylprednisolone Hemisuccinate, Methylprednisolone hydrogen succinate, Methylprednisolone sodium succinate (JAN/USP) + [10] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (18 May 1959), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC26H34NaO8 |
InChIKeyWOARBZBOZOGFGA-SGJOWKDISA-N |
CAS Registry2375-03-3 |
Related
57
Clinical Trials associated with Methylprednisolone sodium succinateNCT06921616
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
NCT06924983
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage.
NCT06462781
Intra-Arterial Injection of Lidocaine and Glucocorticoid in the Treatment of Intractable Headaches
100 Clinical Results associated with Methylprednisolone sodium succinate
Login to view more data
100 Translational Medicine associated with Methylprednisolone sodium succinate
Login to view more data
100 Patents (Medical) associated with Methylprednisolone sodium succinate
Login to view more data
1,813
Literatures (Medical) associated with Methylprednisolone sodium succinate01 Jun 2025EXPERIMENTAL PARASITOLOGY
Toll-like receptors and inflammatory cytokines in the skin of Acanthamoeba spp. infected immunocompetent and immunosuppressed mice
Article
Author: Kosik-Bogacka, D ; Derda, M ; Łanocha-Arendarczyk, N ; Kolasa, A ; Kot, K ; Wojtkowiak-Giera, A ; Solarczyk, P
Acanthamoeba spp. can cause opportunistic infections, such as cutaneous acanthamoebiasis (CA). Little is known about the role of TLRs and cytokines in the host skin during Acanthamoeba spp. infections. The study aimed to examine the gene and protein expression of TLR3, TLR7, IFN-γ, and IL-23 in the skin of mice experimentally infected with a clinical strain of Acanthamoeba spp. male BALB/c mice were assigned to four groups: group I (control group I) - with normal immunity (C, n = 5); group II (control group II) - with reduced immunity induced by methylprednisolone sodium succinate (MPS; CS, n = 5); group III - amoeba-infected hosts with normal immunity (A, n = 12); and group IV- amoeba-infected hosts with reduced immunity induced by MPS (AS, n = 12). The skin sections (2 cm × 2 cm) were collected from the animals at 8, 16, and 24 days post-infection (dpi). TLR3, TLR7, IFN-γ, and IL-23 gene and protein expressions were analyzed by quantitative real-time PCR and immunohistochemical staining. In the immunocompetent hosts, we noted higher expressions of TLR3 and IL-23 at all-time points, except 8th dpi when IL-23 gene expression was downregulated compared to the control group. The mRNA expressions of TLR7 and IFN-γ were higher at 16 and 24 dpi in the skin of immunocompetent Acanthamoeba spp.-infected hosts than in the uninfected mice. In the course of acanthamoebiasis in the mice with reduced immunity, we found significant upregulation of TLR3, IL-23, and TLR7 gene expressions only at the beginning of infection compared to the control group. A similar relationship was observed for IFN-γ at 8 and 16 dpi. The pathophysiology of Acanthamoeba infection in the skin is complex. The data presented in this paper add new insight, but they are not sufficient to explain the role of the studied receptors and cytokines. The clinical picture and mechanisms of host response appear to be influenced by the route of infection, immunological status and microorganisms carried within the parasites. CA remains a multifactorial phenomenon.
01 Jun 2025JOURNAL OF CONTROLLED RELEASE
Comparing continuous micromixing and extrusion downsizing for PEGylated nanoliposomes remotely loaded with doxorubicin or the steroid pro-drug methylprednisolone hemisuccinate
Article
Author: Bleul, Regina ; Barenholz, Yechezkel ; Thiermann, Raphael ; Turjeman, Keren ; Paulus, Christine ; Shamrakov, Dima ; Egler-Kemmerer, Alexander-Nicholas
Since the FDA approval of the first nanodrug Doxil® in 1995, twenty subsequent liposome and lipid nanoparticle (LNP) based drugs (of which 10 are nanodrugs), were approved by the FDA. The application of such drug-products was considerably boosted by the mRNA-LNP based vaccines used to stop the COVID-19 pandemic. Research on lipid-based vesicles and nanoparticles for drug delivery dates to the 1970s and has culminated in both continuous flow and extrusion-based fabrication processes for current state-of-the-art GMP industrial production of nanoliposomes and lipid nanoparticles. In this study, we compare these two approaches for the preparation of two PEGylated nanoliposome-based drug-products, keeping all other production steps leading to the final drug-product identical. One of these products, generic Doxil®, is remotely and actively loaded with the anthracycline doxorubicin (an amphipathic weak base) driven by a transmembrane ammonium gradient, while the other is methylprednisolone hemisuccinate (an amphipathic weak acid) remotely and actively loaded via a transmembrane acetate gradient. We demonstrate that a microfluidics-based micromixer approach yields equivalent or even better drug-products, especially since the downsizing by microfluidics is not performed above the temperature range of lipid phase transition. The main difference in the physico-chemical features is that size distribution of the microfluidics prepared PEGylated nano liposomes was significantly narrower and morphological analysis by cryo-TEM confirmed higher homogeneity. An additional advantage of the microfluidic approach is that it is a continuous production. Therefore, it enables the direct production of large volumes of high-quality nano-liposomal based drug-products.
01 May 2025JOURNAL OF PHARMACEUTICAL SCIENCES
Physiologically-based modeling of methylprednisolone pharmacokinetics across species with extrapolations to humans
Article
Author: Yu, Ruihong ; Jusko, William J
Methylprednisolone (MPL) is widely used in clinical and veterinary medicine to manage inflammation. Plasma profiles and PK parameters in 7 species were digitized from 10 literature sources along with our recent PBPK results in rats. Basic allometric scaling provided reported clearance (CL) and distribution volume (Vd) from noncompartmental analysis highly correlated with body weights (R2 > 0.96), although rat CL deviated from the linear trend. A basic nonlinear minimal physiologically-based pharmacokinetic model (mPBPK) (Model I), an intermediate reversible-metabolism mPBPK model (Model II) accounting for MPL and methylprednisone interconversion, and a full highly complex PBPK model were used to assess the interspecies plasma concentration datasets. The MPL PK profiles were reasonably captured by Model I and II, yielding allometric exponents for CL of 1.15 and 0.94, consistent with basic allometry, 1.18. Rat PK informed the presence of nonlinear tissue binding and required an adjustment factor approximately 8-fold higher for its CL. Our full PBPK model was extrapolated from rats to humans using allometry from Model II and optimized producing excellent applications in healthy subjects and patients. This study, based on conserved tissue binding properties, provided three allometric translational PBPK models for MPL, facilitating reasonable PK assessment and interpretation for various species.
100 Deals associated with Methylprednisolone sodium succinate
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Mucocutaneous Lymph Node Syndrome | Japan | 25 Sep 2023 | |
| Churg-Strauss Syndrome | Japan | 29 Aug 2014 | |
| Granulomatosis With Polyangiitis | Japan | 29 Aug 2014 | |
| Polyarteritis Nodosa | Japan | 29 Aug 2014 | |
| Polymyositis | Japan | 29 Aug 2014 | |
| Systemic Lupus Erythematosus | Japan | 29 Aug 2014 | |
| Takayasu Arteritis | Japan | 29 Aug 2014 | |
| Lymphoma | Japan | 29 Aug 2001 | |
| Nephrotic Syndrome | Japan | 29 Aug 2001 | |
| Spinal Cord Injuries | Japan | 29 Aug 2001 | |
| Systemic Vasculitis | Japan | 29 Aug 2001 | |
| Addison Disease | China | 01 Jan 2001 | |
| Anemia | China | 01 Jan 2001 | |
| Asthma | China | 01 Jan 2001 | |
| Dermatomyositis | China | 01 Jan 2001 | |
| Keratitis | China | 01 Jan 2001 | |
| Leukemia | China | 01 Jan 2001 | |
| Multiple Sclerosis | China | 01 Jan 2001 | |
| Pemphigus | China | 01 Jan 2001 | |
| acute spinal cord injury | Japan | 02 Jul 1997 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Malaria, Falciparum | Preclinical | Israel | - | |
| Optic Neuritis | Preclinical | Israel | - | |
| Rheumatoid Arthritis | Preclinical | Israel | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 89 | Low Dose Corticosteroids (Low Dose Corticosteroids) | ekbdvijdyg = oprxhxnccb lzoauancaa (ozmklmwaho, unthgizlkn - dkgeqzubxl) View more | - | 10 Apr 2024 | ||
High Dose Corticosteroids (High Dose Corticosteroids) | ekbdvijdyg = snnlylbezp lzoauancaa (ozmklmwaho, skpoatzbdk - nwlrfzumnk) View more | ||||||
Early Phase 1 | 47 | (Group A: Glucocorticoids 1 mg/kg Dose) | erwmjszywe = btkrmrtqzb vvxwnrwdfk (urxknhqtwq, ljshxqgsvn - vezwlvlluu) View more | - | 21 Aug 2023 | ||
(Group B: Glucocorticoids 250 mg Dose) | erwmjszywe = nipdwzggcq vvxwnrwdfk (urxknhqtwq, mmrbfggdpf - qkizriacuj) View more | ||||||
Phase 1 | - | 33 | (Up to 2 Hours Post Infusion) | rhnlgovkrw = tftvqiwhst xcyzwnbooi (brmmheuycx, srwdgzxmld - wzkmuamawq) View more | - | 22 Jun 2023 | |
Methylprednisolone sodium succinate(Solu-Medrol)+Topical methylprednisolone (Advantan emulsion 0 /1%) (Up to 4 Hours Post Infusion) | rhnlgovkrw = vdwwgjtlqj xcyzwnbooi (brmmheuycx, yomjrtjfyz - cijyvvbvpd) View more | ||||||
Phase 3 | 18 | (Steroid Arm) | svwjowpmof(dwdyrtpxnr) = dqsenkoywa ahlgwhwfhl (cgnzdhetgf, bvffpnivck - qwxahhemgs) View more | - | 07 Jul 2020 | ||
Placebo (Comparison Group) | svwjowpmof(dwdyrtpxnr) = soljkkouff ahlgwhwfhl (cgnzdhetgf, zwwfvzdzic - mqtvfrlxbp) View more | ||||||
Phase 3 | 58 | Total lymphoid irradiation (TLI)+Methylprednisolone sodium succinate+Cyclosporine (CSP)+Anti-thymocyte globulin (ATG)+Mycophenolate mofetil (MMF) (Allo-HSCT + TLI + ATG) | celtfkvvsl = ivdczlzmgy rmiuobccnv (suggqnqlge, powhdwhxxo - fypmhljrqi) View more | - | 11 Sep 2019 | ||
Best standard care (Best Standard Care) | celtfkvvsl = nqxzojhdxe rmiuobccnv (suggqnqlge, slnuefdukv - dqewttcdak) View more | ||||||
Phase 4 | 119 | (Steroid) | bftxrnulff = kcjjosqkit akrllomolx (muwfsxzbdk, bwryltmwsy - cllfuxwxwa) View more | - | 20 Aug 2019 | ||
Placebo (Placebo) | bftxrnulff = lmplnlfyyr akrllomolx (muwfsxzbdk, eqiljxvgwa - orswjiepls) View more | ||||||
Phase 2 | 50 | Antithymocyte globulin+Solu-Medrol+Cyclosporine+Etoposide+CYCLOPHOSPHAMIDE+BCNU+Filgrastim+mycophenolate mofetil+Rituximab | jtebvtpxlw = bsffwjtqwr lbnnxslrjo (deytgdwvrx, wbomqegudu - axcsfbwoqa) View more | - | 14 Feb 2018 | ||
Phase 2 | 9 | Allogeneic peripheral blood stem cells (allo-PBSC) transplantation+Rabbit anti-thymocyte globulin+Cyclosporine+Solumedrol+Acetaminophen+Cyclophosphamide+Filgrastim+Melphalan+Diphenhydramine+Mycophenolate Mofetil 250mg+Hydrocortisone | lapfjnvhyz = sctstmrrqh cffixwozwt (nfgcrwifiu, syzmzvvzbz - huuvuyuvac) View more | - | 20 Oct 2017 | ||
Not Applicable | 211 | (Standard of Care Analgesia) | vaebisvrsr(pauenmhxlf) = zoueynoohy fkuvgnmsod (eqrycbjrjf, hfywofgefk - iryssohhrk) View more | - | 21 Oct 2016 | ||
(Liposomal Bupivacaine) | vaebisvrsr(pauenmhxlf) = yqtojoqwmb fkuvgnmsod (eqrycbjrjf, vebnpbqdzs - fjqpibucoy) View more | ||||||
Phase 3 | 255 | (Oral Steroids) | xptfyzsmjs(hyuusfducx) = vzgovzmpli zwzobeoxuc (qrywpqgryy, 21.7) View more | - | 04 Apr 2013 | ||
methylprednisolone (IT Steroids) | xptfyzsmjs(hyuusfducx) = aqeukzeinb zwzobeoxuc (qrywpqgryy, 21.5) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free